Myriad Genetics controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
2015
Australian BRCA patent litigation
In D'Arcy v Myriad Genetics Inc, the High Court of Australia rejected the patentability of the relevant naturally occurring genetic sequence under Australian law, following earlier decisions that had favored Myriad.
2013
BRCA gene patent controversy and Supreme Court case
Myriad’s efforts to patent and enforce rights relating to BRCA1 and BRCA2 generated criticism from researchers, physicians, patient advocates, and civil-liberties organizations. Critics argued that patents on naturally occurring genes could restrict testing, biomedical research, and patient access. The United States Supreme Court ultimately ruled that naturally occurring DNA is not patent-eligible merely because it has been isolated.